m6A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop
Cancer Letters · 2024-08 · 596 · 217004
DOI: 10.1016/j.canlet.2024.217004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Yibo Bian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China; State Key Laboratory of Holistic Integrativ…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Ferroptosis, RNA, Long Noncoding, Forkhead Box Protein M1. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Long non-coding RNA (lncRNA) is closely related to a variety of human cancers, which may provide huge potential biomarkers for cancer diagnosis and treatment. However, the aberrant expression of most lncRNAs in colorectal cancer (CRC) remains elusive. This study aims to explore the clinical significance and potential mechanism of lncRNA ABHD11 antisense RNA 1 (ABHD11-AS1) in the colorectal cancer. Here, we demonstrated that lncRNA ABHD11-AS1 is high-expressed in colorectal cancer (CRC) patients, and strongly related with poor prognosis. Functionally, ABHD11-AS1 suppresses ferroptosis and promotes proliferation and migration in CRC both in vitro and in vivo. Mechanically, lncRNA ABHD11-AS1 interacted with insulin-like growing factor 2 mRNA-binding protein 2 (IGF2BP2) to enhance FOXM1 stability, forming an ABHD11-AS1/FOXM1 positive feedback loop. E3 ligase tripartite motif containing 21 (TRIM21) promotes the degradation of IGF2BP2 via the K48-ubiquitin-lysosome pathway and ABHD11-AS1 promotes the interaction between IGF2BP2 and TRIM21 as scaffold platform. Furthermore, N6 -adenosine-methyltransferase-like 3 (METTL3) upregulated the stabilization of ABHD11-AS1 through the m6A reader IGF2BP2. Our study highlights ABHD11-AS1 as a significant regulator in CRC and it may become a potential target in future CRC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Researc…
- Department of Oncology, Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
- Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
- Department of General Surgery, Zhongshan Hospital, Fudan University School of Medicine, Shanghai, 200032, China.
- Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
- Department of Oncology, Lianshui County People's Hospital, Huai'an, 223400, China. Electronic address: lspuj@sina.com.
Zitieren
APA
Bian, Y., Xu, S., Gao, Z., Ding, J., Li, C., Cui, Z., Sun, H., Li, J., Pu, J., & Wang, K. (2024). m6A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop. Cancer Letters, 596, 217004. https://doi.org/10.1016/j.canlet.2024.217004
Vancouver
Bian Y, Xu S, Gao Z, Ding J, Li C, Cui Z, et al. m6A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop. Cancer Letters. 2024;596:217004. doi:10.1016/j.canlet.2024.217004
BibTeX
@article{Bian2024,
author = {Bian, Yibo and Xu, Shufen and Gao, Zhishuang and Ding, Jie and Li, Chao and Cui, Zhiwei and Sun, Haoyu and Li, Juan and Pu, Juan and Wang, Keming},
title = {m6A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop},
journal = {Cancer Letters},
year = {2024},
volume = {596},
pages = {217004},
doi = {10.1016/j.canlet.2024.217004}
}
EUVIMED